ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SAR Sareum Holdings Plc

11.00
-3.50 (-24.14%)
Last Updated: 13:25:38
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.50 -24.14% 11.00 10.50 11.50 12.00 10.50 12.00 6,861,008 13:25:38
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -3.19M -0.0469 -2.35 7.49M

Sareum Holdings PLC Advisers (3960R)

15/06/2018 7:00am

UK Regulatory


Sareum (LSE:SAR)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Sareum Charts.

TIDMSAR

RNS Number : 3960R

Sareum Holdings PLC

15 June 2018

 
 (AIM: SAR)   15 June 2018 
 

Sareum Holdings PLC

("Sareum" or "the Company")

Advisers

The Company announces that henceforth WH Ireland Limited will act as Nominated Adviser and Hybridan LLP will act as Sole Broker to the Company.

For further information, please contact:

 
Sareum Holdings plc 
Tim Mitchell                           01223 497 700 
WH Ireland Limited (Nominated Adviser) 
Chris Fielding / James Sinclair-Ford   020 7220 1666 
Hybridan LLP (Broker) 
Claire Noyce                           020 3764 2341 
Citigate Dewe Rogerson (Media 
 enquiries) 
Shabnam Bashir/ Mark Swallow/ 
 David Dible                           020 7282 9571 
 

Notes for editors:

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and undergoing Phase 2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in genetically defined patients both as a monotherapy and in combination with other oncology and immuno-oncology drugs.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPMMGMVLDGGRZG

(END) Dow Jones Newswires

June 15, 2018 02:00 ET (06:00 GMT)

1 Year Sareum Chart

1 Year Sareum Chart

1 Month Sareum Chart

1 Month Sareum Chart

Your Recent History

Delayed Upgrade Clock